Radosveta Gencheva

Radosveta Gencheva

Auto-generated profile, based on publicly available information

Radosveta Gencheva

Division of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, 17177, Sweden

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2021 in Redox Biology
Verified
Journal Article
Open access
PSPierre Sabatier
Pierre Sabatier
CBChristian M. Beusch
Christian M. Beusch
RGRadosveta Gencheva
Radosveta Gencheva
QCQing Cheng
Qing Cheng
JZJanet Zubarev
Janet Zubarev
EAElias Arner
Elias Arner
Anticancer drugs that target cellular antioxidant systems have recently attracted much attention. Auranofin (AF) is currently evaluated in several clinical trials as an anticancer agent that targets the cytosolic and mitochondrial forms of the selenoprotein thioredoxin reductase, TXNRD1 and TXNRD2. Recently, two novel TXNRD1 inhibitors (TRi-1 and TRi-2) have been developed that showed anticancer efficacy comparable to AF, but with lower mitochondrial toxicity. However, the cellular action mechanisms of these drugs have not yet been thoroughly studied. Here we used several proteomics approaches to determine the effects of AF, TRi-1 and TRi-2 when used at IC50 concentrations with the mouse B16 melanoma and LLC lung adenocarcinoma cells, as these are often used for preclinical mouse models in evaluation of anticancer drugs. The results demonstrate that TRi-1 and TRi-2 are more specific TXNRD1 inhibitors than AF and reveal additional AF-specific effects on the cellular proteome. Interestingly, AF triggered stronger Nrf2-driven antioxidant responses than the other two compounds. Furthermore, AF affected several additional proteins, including GSK3A, GSK3B, MCMBP and EEFSEC, implicating additional effects on glycogen metabolism, cellular differentiation, inflammatory pathways, DNA replication and selenoprotein synthesis processes. Our proteomics data provide a resource for researchers interested in the multidimensional analysis of proteome changes associated with oxidative stress in general, and the effects of TXNRD1 inhibitors and AF protein targets in particular.

4 March 2022 in Redox Biology
Verified
Journal Article
Open access
FFFrancesca Fata
Francesca Fata
RGRadosveta Gencheva
Radosveta Gencheva
QCQing Cheng
Qing Cheng
RLRachel Lullo
Rachel Lullo
Matteo ArdiniMatteo Ardini
Matteo Ardini
FAFrancesco Angelucci
Francesco Angelucci
Enzymes in the thiol redox systems of microbial pathogens are promising targets for drug development. In this study we characterized the thioredoxin reductase (TrxR) selenoproteins from Brugia malayi and Onchocerca volvulus, filarial nematode parasites and causative agents of lymphatic filariasis and onchocerciasis, respectively. The two filarial enzymes showed similar turnover numbers and affinities for different thioredoxin (Trx) proteins, but with a clear preference for the autologous Trx. Human TrxR1 (hTrxR1) had a high and similar specific activity versus the human and filarial Trxs, suggesting that, in vivo, hTrxR1 could possibly be the reducing agent of parasite Trxs once they are released into the host. Both filarial TrxRs were efficiently inhibited by auranofin and by a recently described inhibitor of human TrxR1 (TRi-1), but not as efficiently by the alternative compound TRi-2. The enzyme from B. malayi was structurally characterized also in complex with NADPH and auranofin, producing the first crystallographic structure of a nematode TrxR. The protein represents an unusual fusion of a mammalian-type TrxR protein architecture with an N-terminal glutaredoxin-like (Grx) domain lacking typical Grx motifs. Unlike thioredoxin glutathione reductases (TGRs) found in platyhelminths and mammals, which are also Grx–TrxR domain fusion proteins, the TrxRs from the filarial nematodes lacked glutathione disulfide reductase and Grx activities. The structural determinations revealed that the Grx domain of TrxR from B. malayi contains a cysteine (C22), conserved in TrxRs from clade IIIc nematodes, that directly interacts with the C-terminal cysteine-selenocysteine motif of the homo-dimeric subunit. Interestingly, despite this finding we found that altering C22 by mutation to serine did not affect enzyme catalysis. Thus, although the function of the Grx domain in these filarial TrxRs remains to be determined, the results obtained provide insights on key properties of this important family of selenoprotein flavoenzymes that are potential drug targets for treatment of filariasis.

1 October 2022 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
AAAndrey Alexeyenko
Andrey Alexeyenko
OBOdd Terje Brustugun
Odd Terje Brustugun
IEInger Johanne Zwicky Eide
Inger Johanne Zwicky Eide
RGRadosveta Gencheva
Radosveta Gencheva
ZKZeinab Kosibaty
Zeinab Kosibaty
SESimon Ekman
Simon Ekman
Original Article Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients Andrey Alexeyenko, Odd Terje Brustugun, Inger Johanne Zwicky Eide, Radosveta Gencheva, Zeinab Kosibaty, Yi Lai, Luigi de Petris, Georgios Tsakonas, Oscar Grundberg, Bo Franzen, Kristina Viktorsson, Rolf Lewensohn, Per Hydbring, Simon Ekman

8 November 2024
Verified
Preprint
Open access
PDF file
RGRadosveta Gencheva
Radosveta Gencheva
The increased understanding of the role of redox homeostasis in cancer survival and progression has placed a spotlight on studying the perturbations in redox signaling as cancer vulnerabilities. These vulnerabilities are in part under the control of antioxidant systems such as the thioredoxin system, with its main effector, the selenoprotein thioredoxin reductase (TXNRD). The selenocysteine- containing (Sec) active site of TXNRD is highly susceptible to alkylation by electrophiles and this has in fact been shown to be a part of the mechanism of action of a range of anticancer compounds in the clinic and in trials, including cisplatin and auranofin. Discovering and developing compounds with a focused target profile on TXNRD has been a major aim of the Arner group, so as to limit the side effects seen with drugs with broader target profiles and to study the precise downstream effects of TXNRD inhibition on redox signaling in cancer. These efforts led to the discovery of thioredoxin reductase inhibitor 1 (TRi-1), a highly selective TXNRD inhibitor with good antitumoral activity in mouse models. This thesis has focused on further characterizing the effects of TRi-1 in cancer cells and better understanding the role of TXNRD as a cancer vulnerability.Paper I further confirmed the narrow target profile of TRi-1 in comparison to auranofin on a proteomics scale by combining thermal proteome profiling, protein expression and redox proteomics approaches. It also established that TRi-1 does not result in a stable downregulation of cellular TXNRD activity, but instead causes rapid inhibition followed by a compensatory increase.In Paper II, we explored the activities of TRi-1 analogs with functionalizations allowing for increased mitochondrial uptake or differential electrophilicity of the selenocysteine-interacting moiety, both against cytosolic and mitochondrial TXNRD isoforms. We arrived at a diverse collection of novel compounds with a range of efficacies in recombinant systems and cancer cell lines, including scaffolds with improved activity compared to TRi-1.Paper III identified surprising connections between TXNRD and ferroptosis by confirming ferroptosis inducers as inhibitors of TXNRD and by establishing that TRi-1-induced cell death cannot be classified as ferroptosis and indeed cannot be rescued by any of the most common death inhibitors. We also reported differential glutathione peroxidase 4 migration patterns in response to ferroptosis inducing TXNRD1 inhibitors and TRi-1, hinting their effects on antioxidant systems in recombinant and cellular contexts are more complex than previously anticipated.Paper IV characterized in detail the kinetics of cellular events taking place after TRi-1 and thereby comprehensively portrayed the mechanisms of action of this compound in cancer cells. We established that short term exposure of the cells, in the order of one hour, to the compound is in every way equivalent to a continuous exposure and showed the kinetics of TRi-1 derivatization of the TXNRD selenopeptide in cells. The anticancer effects were predominantly caused by an arrest in cell cycle progression characterized by a downregulation of CDK1/2. Cells experienced peroxiredoxin dimerization and overoxidation, suggestive of increased oxidative stress, but without major perturbations in protein or nucleotide homeostasis.Paper V established the efficacy of TRi-1 in parasite TXNRD isoforms with unusual structural domains, suggesting that a broader application of this compound to pathologies beyond cancer may be possible, much like the broader indications for using the more promiscuous auranofin.Overall, the papers comprising this thesis have focused on exploring different aspects of the mechanism of action of TRi-1 as a TXNRD inhibitor and have painted a multifaceted picture of the compound's activities extending far beyond its target engagement.List of scientific papersI. Pierre Sabatier, Christian M. Beusch, Radosveta Gencheva, Qing Cheng, Roman Zubarev, Elias S.J. Arnér. Comprehensive chemical proteomics analyses reveal that the new TRi-1 and TRi-2 compounds are more specific thioredoxin reductase 1 inhibitors than auranofin. Redox Biol. 2021 Nov 11;48:102184. https://doi.org/10.1016/j.redox.2021.102184II. Miloš Jović#, Radosveta Gencheva #, Qing Cheng, Karoline C. Scholzen, Života Selaković, Elias S.J. Arnér, Igor M. Opsenica. Development of novel analogs of the TRi-1 and TRi-2 selenoprotein thioredoxin reductase inhibitors with initial assessment of their cytotoxicity profiles. [Submitted]III. Dorian M. Cheff, Chuying Huang, Karoline C. Scholzen, Radosveta Gencheva, Michael H. Ronzetti, Qing Cheng, Matthew D. Hall, Elias S. J. Arnér. The ferroptosis inducing compounds RSL3 and ML162 are not direct inhibitors of GPX4 but of TXNRD. Redox Biol. 2023 Jun;62:102703. https://doi.org/10.1016/j.redox.2023.102703IV. Radosveta Gencheva, Giovanni Chiappetta, Karoline C. Scholzen, Praveen Pandey, Zhao Wenchao, Lucia Coppo, Qing Cheng, Joelle Vinh, Andrei Chabes, Elias S.J. Arnér. Insights into the kinetics of thioredoxin reductase derivatization and associated cancer cell death by the small molecule inhibitor TRi-1. [Manuscript]V. Francesca Fata#, Radosveta Gencheva #, Qing Cheng, Rachel Lullo, Matteo Ardini, Ilaria Silvestri, Federica Gabriele, Rodolfo Ippoliti, Christina A. Bulman, Judy A. Sakanari, David L. Williams, Elias S.J. Arnér, Francesco Angelucci. Biochemical and structural characterizations of thioredoxin reductase selenoproteins of the parasitic filarial nematodes Brugia malayi and Onchocerca volvulus. Redox Biol. 2022 May;51:102278. https://doi.org/10.1016/j.redox.2022.102278


8 November 2024
Verified
Preprint
Open access
PDF file
RGRadosveta Gencheva
Radosveta Gencheva
The increased understanding of the role of redox homeostasis in cancer survival and progression has placed a spotlight on studying the perturbations in redox signaling as cancer vulnerabilities. These vulnerabilities are in part under the control of antioxidant systems such as the thioredoxin system, with its main effector, the selenoprotein thioredoxin reductase (TXNRD). The selenocysteine- containing (Sec) active site of TXNRD is highly susceptible to alkylation by electrophiles and this has in fact been shown to be a part of the mechanism of action of a range of anticancer compounds in the clinic and in trials, including cisplatin and auranofin. Discovering and developing compounds with a focused target profile on TXNRD has been a major aim of the Arner group, so as to limit the side effects seen with drugs with broader target profiles and to study the precise downstream effects of TXNRD inhibition on redox signaling in cancer. These efforts led to the discovery of thioredoxin reductase inhibitor 1 (TRi-1), a highly selective TXNRD inhibitor with good antitumoral activity in mouse models. This thesis has focused on further characterizing the effects of TRi-1 in cancer cells and better understanding the role of TXNRD as a cancer vulnerability.Paper I further confirmed the narrow target profile of TRi-1 in comparison to auranofin on a proteomics scale by combining thermal proteome profiling, protein expression and redox proteomics approaches. It also established that TRi-1 does not result in a stable downregulation of cellular TXNRD activity, but instead causes rapid inhibition followed by a compensatory increase.In Paper II, we explored the activities of TRi-1 analogs with functionalizations allowing for increased mitochondrial uptake or differential electrophilicity of the selenocysteine-interacting moiety, both against cytosolic and mitochondrial TXNRD isoforms. We arrived at a diverse collection of novel compounds with a range of efficacies in recombinant systems and cancer cell lines, including scaffolds with improved activity compared to TRi-1.Paper III identified surprising connections between TXNRD and ferroptosis by confirming ferroptosis inducers as inhibitors of TXNRD and by establishing that TRi-1-induced cell death cannot be classified as ferroptosis and indeed cannot be rescued by any of the most common death inhibitors. We also reported differential glutathione peroxidase 4 migration patterns in response to ferroptosis inducing TXNRD1 inhibitors and TRi-1, hinting their effects on antioxidant systems in recombinant and cellular contexts are more complex than previously anticipated.Paper IV characterized in detail the kinetics of cellular events taking place after TRi-1 and thereby comprehensively portrayed the mechanisms of action of this compound in cancer cells. We established that short term exposure of the cells, in the order of one hour, to the compound is in every way equivalent to a continuous exposure and showed the kinetics of TRi-1 derivatization of the TXNRD selenopeptide in cells. The anticancer effects were predominantly caused by an arrest in cell cycle progression characterized by a downregulation of CDK1/2. Cells experienced peroxiredoxin dimerization and overoxidation, suggestive of increased oxidative stress, but without major perturbations in protein or nucleotide homeostasis.Paper V established the efficacy of TRi-1 in parasite TXNRD isoforms with unusual structural domains, suggesting that a broader application of this compound to pathologies beyond cancer may be possible, much like the broader indications for using the more promiscuous auranofin.Overall, the papers comprising this thesis have focused on exploring different aspects of the mechanism of action of TRi-1 as a TXNRD inhibitor and have painted a multifaceted picture of the compound's activities extending far beyond its target engagement.List of scientific papersI. Pierre Sabatier, Christian M. Beusch, Radosveta Gencheva, Qing Cheng, Roman Zubarev, Elias S.J. Arnér. Comprehensive chemical proteomics analyses reveal that the new TRi-1 and TRi-2 compounds are more specific thioredoxin reductase 1 inhibitors than auranofin. Redox Biol. 2021 Nov 11;48:102184. https://doi.org/10.1016/j.redox.2021.102184II. Miloš Jović#, Radosveta Gencheva #, Qing Cheng, Karoline C. Scholzen, Života Selaković, Elias S.J. Arnér, Igor M. Opsenica. Development of novel analogs of the TRi-1 and TRi-2 selenoprotein thioredoxin reductase inhibitors with initial assessment of their cytotoxicity profiles. [Submitted]III. Dorian M. Cheff, Chuying Huang, Karoline C. Scholzen, Radosveta Gencheva, Michael H. Ronzetti, Qing Cheng, Matthew D. Hall, Elias S. J. Arnér. The ferroptosis inducing compounds RSL3 and ML162 are not direct inhibitors of GPX4 but of TXNRD. Redox Biol. 2023 Jun;62:102703. https://doi.org/10.1016/j.redox.2023.102703IV. Radosveta Gencheva, Giovanni Chiappetta, Karoline C. Scholzen, Praveen Pandey, Zhao Wenchao, Lucia Coppo, Qing Cheng, Joelle Vinh, Andrei Chabes, Elias S.J. Arnér. Insights into the kinetics of thioredoxin reductase derivatization and associated cancer cell death by the small molecule inhibitor TRi-1. [Manuscript]V. Francesca Fata#, Radosveta Gencheva #, Qing Cheng, Rachel Lullo, Matteo Ardini, Ilaria Silvestri, Federica Gabriele, Rodolfo Ippoliti, Christina A. Bulman, Judy A. Sakanari, David L. Williams, Elias S.J. Arnér, Francesco Angelucci. Biochemical and structural characterizations of thioredoxin reductase selenoproteins of the parasitic filarial nematodes Brugia malayi and Onchocerca volvulus. Redox Biol. 2022 May;51:102278. https://doi.org/10.1016/j.redox.2022.102278